TTR and hepatocellular carcinoma: The patients bearing HCC with above-medium levels of both 14-3-3β and p-Akt suffered exacerbated adverse clinical outcomes compared with those with below-medium levels of both 14-3-3β and p-Akt (OS, p<0.001; TTR, p<0.001; Fig 5C & 5D).